Patient-derived xenograft (PDX) tumor models retain much of the biological diversity and heterogeneity of the original patient tumor. Recent advances in the development of these models and the models’ increasing sophistication have led to their greater use for anticancer drug research and development and as predictive clinical models.
In this webinar experts from the University of California, Davis Comprehensive Cancer Center will describe their experience using PDX tumor models derived from fresh clinical samples of human lung and bladder tumors. Philip C. Mack, Ph.D., and Chong-Xian Pan, M.D., Ph.D., will discuss whole exome, transcriptome, and microRNA sequencing, followed by computational biological analysis to identify genetic alterations validated with immunofluorescence and immunohistochemical staining.
The presenters will also discuss the details of PDX molecular characterization studies, including driver mutations and copy number variation. In addition, the implications of recent PDX studies for patient selection and treatment algorithms will be addressed.
In this webinar you will learn:
Registration is Open